Foreign direct investment in Europe by multinational pharmaceutical companies from India

Journal of Economic Geography

Volumn 12, Issue 4, 2012, Pages 809-839

  Kedron, Peter ^a   Bagchi Sen, Sharmistha ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

Emerging market multinational enterprise (EMMNE); Europe; Foreign direct investment; Indian pharmaceuticals

Indexed keywords

CORPORATE STRATEGY; DECISION MAKING; ECONOMIC GROWTH; FOREIGN DIRECT INVESTMENT; INDUSTRIAL INVESTMENT; MARKET CONDITIONS; MULTINATIONAL ENTERPRISE; PHARMACEUTICAL INDUSTRY;

EUROPE; INDIA;

EID: 84863454866     PISSN: 14682702     EISSN: 14682710     Source Type: Journal    
DOI: 10.1093/jeg/lbr044     Document Type: Article

References (91)

1. Agarwal, S., Ramaswami, S. (1992) Choice of foreign market entry mode: impact of ownership, location, and internalization factors. Journal of International Business Studies, 23: 1-27.
2. Ashurst. (2005) EU-v-US generic pharmaceutical regulation. (Published August 2008), Available online at: http://www.ashurst.com [Accessed 15 January 2010].
3. Benito, G. R., Petersen, B., Welch, L. S. (2009) Towards more realistic conceptualizations of foreign operation modes. Journal of International Business Studies, 40: 1455-1470.
4. Bhaumik, S. K., Driffield, N. D., Pal, S. (2010) Does ownership structure of emerging-market firms affect their outward FDI? The case of Indian automobile and pharmaceutical sectors. Journal of International Business Studies, 41: 437-450.
5. Blake, R., Burau, V. (2007) Comparative Health Policy. Houndmills: Palgrave Macmillan.
6. Bodenheimer, T. (2005) High and rising health care costs. Part 2: technological innovation. Annals of Internal Medicine, 142: 932-937.
7. Brenner, G., Rublee, D. (2002) Germany. In B. Fried, L. M. Gaydos (eds) World Health Systems: Challenges and Perspectives. Chicago: Health Administration Press.
8. Broadman, H. G. (2008) China and India go to Africa: new deals in the developing world. Foreign Affairs, 87: 1-6.
9. Buckley, P. J. (2002) Is the international business research agenda running out of steam? Journal of International Business Studies, 33: 365-373.
10. Buckley, P. J., Casson, M. (1976) The Future of Multinational Enterprise. New York: Holmes and Meier Publishers.
11. Buckley, P. J., Casson, M. (1985) The Economic Theory of the Multinational Enterprise. London: MacMillian St Martin's Press.
12. Buckley, P. J., Casson, M. (2007) Edith Penrose's theory of the growth of the firm and the stratefic management of multinational enerprises. Management International Review, 47: 151-173.
13. Buckley, P. J., Casson, M. (2009) The internalization theory of the multinational enterprise: a review of the progress of a research agenda after 30 years. Journal of International Business Studies, 40: 1563-1580.
14. Buckley, P. J., Casson, M. (2011) Marketing and the multinational: extending internalization theory. Journal of the Academy of Marketing Science, Advance Access publication 7 January 2011, doi: 10.1007/s11757-010-0243-0.
15. Buckley, P. J., Lessard, D. R. (2005) Regaining the edge in international business research. Journal of International Business Studies, 36: 595-599.
16. Buckley, P. J., Clegg, J. L., Cross, A. R., Liu, X., Voss, H., Zheng, P. (2007) The determinants of Chinese outward foreign direct investment. Journal of International Business Studies, 38: 499-518.
17. Buckley, P. J., Forsans, N., Munjal, S. (2010) Host-Source country linkages as determinants of foreign acquisitions by Indian MNEs. 36th Annual European International Business Academy, 9 December 2010-11 December 2010, Porto.
18. Busse, R., Scheryogg, J., Henke, K.-D. (2005) Regulation of pharmaceutical markets in Germany: improving efficiency and controlling expenditures? International Journal of Health Planning and Management, 20: 329-349.
19. Calvet, A. L. (1981) A synthesis of foreign direct investment theories and theories of the multinational firm. Journal of International Business Studies, 12: 43-59.
20. Cantwell, J., Janne, O. (1999) Technological globalization and innovation centres: the role of corporate technological leadership and locational hierarchy. Research Policy, 28: 119-144.
21. Caves, R. E. (1971) International corporations: the industrial economics of foreign investment. Economica, 38: 1-27.
22. Caves, R. E. (1980) Industrial organization, corporate strategy and structure. Journal of Economic Literature, 18: 64-92.
23. Caves, R. E. (2007) Multinational Enterprise and Economic Analysis. Cambridge: Cambridge University Press.
24. Costich, J. F. (2002) France. In B. Fried, L. M. Gaydos (eds) World Health Systems: Challenges and Perspectives, pp. 153-172. Chicago: Health Administration Press.
25. Datamonitor. (2009a) Generics in Europe: industry profile. (Published August 2008), Available online at: http://www.datamonitor.com [Accessed 12 November 2009].
26. Datamonitor. (2009b) Generics in Germany: industry profile. (Published July 2009), Available online at: http://www.datamonitor.com [Accessed 12 November 2009].
27. Datamonitor. (2009c) Pharmaceuticals in the United Kingdom: industry profile. (Published November 2008), Available online at: http://www.datamonitor.com [Accessed 12 November 2009].
28. Datamonitor. (2009d) Generics in France: industry profile. (Published July 2009), Available online at: http://www.datamonitor.com [Accessed 12 November 2009].
29. Dicken, P. (1992) International production in a volatile regulatory environment: the influence of national regulatory policies on the spatial strategies of transnational corporations. Geoforum, 23(3): 303-316.
30. Dr Reddy's. (2010) Milestones. (Published 2002), Available online at: http://www.drreddys.com/ 25yearsofhealth/milestones_growing_2002.shtml [Accessed 11 December 2009].
31. Dunning, J. H. (1980) Toward an eclectic theory of international production: some empirical tests. Journal of International Business Studies, 11: 9-31.
32. Dunning, J. H. (1995) Reapprasing the eclectic paradigm in an age of alliance capitalism. Journal of International Business Studies, 26: 461-492.
33. Dunning, J. H. (2000) The eclectic paradigm as an envelope for economic and business theories of MNE activity. International Business Review, 9: 163-190.
34. Dunning, J. H. (2003) Some antecedents of internalization theory. Jounral of International Business Studies, 34: 103-115.
35. Dunning, J. H. (2006) Comment on dragon multinationals: new players in 21st century globalization. Asia Pacific Journal of Management, 23: 139-141.
36. Dunning, J. H., Lundan, S. (2008) Multinational Enterprises and the Global Economy. Northampton: Edward Elgar Publishing.
37. Erramilli, M. K., Agarwal, S., Kim, S. S. (1997) Are firm-specific advantages location-specific too? Journal of International Business Studies, 28: 735-757.
38. Ess, S. M., Schneeweiss, S., Szucs, T. D. (2003) European healthcare policies for controlling drug expenditures. PharmacoEconomices, 21: 89-103.
39. European Commission. (2009) Pharmaceutical Sector Inquiry. Paris: European Commission (Published 8 July 2009), Available online at: http://ec.europa.eu/competition/sectors/pharma ceuticals/inquiry [Accessed 12 November 2009].
40. Express Pharma. (2008) DRL signs definitive agreement with Dow Chemicals. Available online at: http://www.expresspharmaonline.com/20080430/market07.shtml [Accessed 5 September 2009].
41. Garg, M., Delios, A. (2007) Survival of the foreign subsidiaries of TMNCs: the influence of business group affiliation. Journal of International Management, 13: 278-295.
42. Gertler, M., Levitte, Y. (2005) Local nodes in global networks: the geography of knowledge flows in biotechnology innovation. Industry and Innovation, 12: 487-507.
43. Graham, E. M. (1974) Oligopolistic Imitation and European Direct Investment in the United States. Doctoral Dissertation, Harvard Business School.
44. Greene, W. (2007) The emergence of India's pharmaceutical industry and implications for the U.S. generic drug market. Office of Economics Working Papers - US International Trade Commission.
45. Griffith, D. A., Cavusgil, S. T., Xu, S. (2008) Emerging themes in international business research. Journal of International Business Studies, 39: 1220-1235.
46. Gubbi, S. R., Aulakh, P. S., Ray, S., Sarkar, M. B., Chittoor, R. (2010) Do international acquisitions by emerging-economy firms create shareholder value? The case of Indian firms. Journal of International Business Studies, 41: 397-418.
47. Gupta, A. (2006) Emergence of Indian multinationals. Technology Exports, 8: 1-12.
48. Hindu Business Line. (2006) Ranbaxy buys Romanian co Terapia for RS 1,445 cr. The Hindu Business Line, (Published 30 March), Available online at: http://www.thehindubusinessline.com [Accessed 5 September 2009].
49. Hoenen, A. K., Hansen, M. W. (2009) Oligopolistic competition and foreign direct investment: re-integrating the strategic management perspective in the theory of multinational corporations. CBDS Working Paper Series, 10.
50. Hoffman, J. (2005) Generics growth in the USA and the EU: the role of India. Journal of Generic Medicines, 3: 7-19.
51. Hymer, S. (1976) The International Operations of National Firms: A Study of Direct Investment. Cambridge, MA: MIT Press.
52. Kedron, P., Bagchi-Sen, S. (2011) US market entry processes if emerging multinationals: a case of Indian pharmaceuticals. Journal of Applied Geography, 31: 721-730.
53. Kermani, F. (2010) Germany's discount contracts are changing the pharma market landscape. Available online at: http://thepinksheetdaily.elsevierbi.com [Accessed 10 March 2011].
54. Knickerbocker, F. T. (1973) Oligopolistic Reaction and Multinational Enterprise. Cambridge, MA: Harvard Business School Division of Research.
55. Kindleberger, C. P. (1969) American Business Abroad: Six Lectures on Direct Investment. New Haven, CT: Yale University Press.
56. Kogut, B., Zander, U. (1993) Knowledge of the firma and the evolutionary theory of the multinational corporation. Journal of International Business Studies, 4: 625-645.
57. Kumar, N. (2008) Internationalization of Indian enterprises: patterns, strategies, ownership advantages, and implications. Asian Economic Policy Review, 3: 242-261.
58. Lall, R. B. (1983) The New Multinationals: The Spread of Third World Enterprises. Paris: John Wiley and Sons.
59. Lall, R. B. (1986) Multinationals from the Third World: Indian Firms Investing Abroad. New York, NY: Oxford University Press.
60. Langley, A. (1999) Strategies for theorizing from process data. The Academy of Management Review, 24: 691-710.
61. Lieverdink, H., van der Made, J. H. (1997) The reform of health insurance systems in the Netherlands and Germany: Dutch gold and German silver. In C. Altenstetter, J. W. Bjorkam (eds) Health Policy Reform, National Variations and Globalization. London: Macmillan.
62. Luo, Y. (2000) Dynamic capabilities in international expansion. Journal of World Business, 35: 355-378.
63. Luo, Y., Tung, R. L. (2007) International expansion of emerging market enterprises: a springboard perspective. Journal of International Business Studies, 38: 481-498.
64. Mathews, J. (2006) Dragon multinationals: new players in 21st century globalization. Asia Pacific Journal of Management, 23: 5-27.
65. Meyer, K., Peng, M. W. (2005) Probing theoretically into Central and Eastern Europe: Transactions, resources, and institutions. Journal of International Business Studies, 36: 600-621.
66. McKelvey, M. (2004) Evolutionary economics perspectives on the regional - national - international dimensions of biotechnology innovations. Environment and Planning C: Government and Policy, 22: 179-197.
67. Mills, A., Ranson, M. K. (2001) The design of health systems. In M. Merson, R. Black, A. Mills (eds) International Public Health: Diseases, Programs, Systems, and Policies. Gaithersburg: AspenPublishers Inc.
68. Morgan, M. (1999) Governing the Health Care State: A Comparative Study of the United Kingdom, United States, and Germany. Manchester: Manchester University Press.
69. Mossialos, E., Oliver, A. (2005) An overview of pharmaceutical policies in four countries: France, Germany, the Netherlands and the United Kingdom. International Journal of Health Panning and Management, 20: 291-306.
70. Mukherjee, W. (2005) Pharma firms look at Europe as going gets tough. The Economic Times, 26 February 2005.
71. Niosi, J., Tschang, T. (2009) The strategies of Chinese and Indian software multinationals: implications for internationalization theory. Industrial and Corporate Change, 18: 269-294.
72. Paris, V. (2005) Pharmaceutical regulation in France 1980-2003. International Journal of Health Planning and Management, 20: 307-328.
73. Peng, M. W. (2004) Identifying the big question in international business research. Journal of International Business Studies, 35: 99-108.
74. Piramal, G. (1996) Business Maharajas. New Delhi: Penguin Books.
75. Pradhan, J. P. (2007a) Growth of Indian multinationals in the world economy: implications for development. Institute for Studies in Industrial Development. Available online at: http://mpra.ub.uni-muenchen.de/12360/ [Accessed 15 January 2011].
76. Pradhan, J. P. (2007b) Trends and patterns of overseas acquisitions by Indian multinationals. Institute for Studies in Industrial Development. Available online at: http://papers.ssrn.com/sol3/papers.cfm?abstract_id=1515632&http://scholar.google.com/scholar?q=Pradhan,+ J.P.+%282007%29+Trends+and+patterns+of+overseas+acquisitions+by+Indian+multi nationals.&hl=en&as_sdt=0&as_vis=1&oi=scholart [Accessed 15 May 2011].
77. Pradhan, J. P. (2008a) Indian Multinationals in the World Economy: Implications for Development. New Delhi: Bookwell.
78. Pradhan, J. P. (2008b) India's emerging multinationals in developed region. Institute for Studies in Industrial Development. Available online at: http://papers.ssrn.com/sol3/papers.cfm? abstract_id=1515667 [Accessed 15 May 2011].
79. Pradhan, J. P., Abraham, V. (2005) Overseas mergers and acquisiitons by Indian enterprises: patterns and motivations. Indian Journal of Economics, 85: 365-386.
80. Ramamurti, R. (2008) What have we learned about EMNEs. In R. Ramaurti, J. Singh (eds) Emerging Multinationals from Emerging Markets. Cambridge: Cambridge University Press.
81. Rugman, A. M. (1985) Internalization is still a general theory of foreign direct investment. Review of World Economics, 121: 570-575.
82. Salehizadeh, M. (2007) Emerging economies' multinationals: current status and future prospects. Third World Quarterly, 28: 1151-1166.
83. Sun, S. L., Peng, M. W., Ren, B., Yan, D. (2010) A comparative ownership advantage framework for cross-border M&As: the rise of Chinese and Indian MNEs. Journal of World Business, Advance Access publication 4 November 2010, doi: 10.1016/j/jwb.2010.10.15.
84. Taylor, H., Nolke, A. (2008) Regulatory governance and the rise of non-triad multinational companies: a modified "Varieties of Capitalism" perspective on Indian multinationals, ECPR Standing Group on Regulatory Governance Conference, Utrecht, 5 June 2008-7 June 2008.
85. Verbeke, A. (2003) The evolutionary view of the MNE and the future of internalization theory. Journal of International Business Studies, 34: 498-504.
86. Wadhwa, V., Rissing, B., Gereffi, G., Trumpbour, J., Engardio, P. (2008) The globalization of innovation: Can India and China cure the global pharmaceutical market. Kansas City: The Kauffman Foundation (Published June 2008), Available online at: http://www.kauffman.org [Accessed 8 September 2009].
87. Walley, T., Mrazek, M., Mossialos, E. (2005) Regulating pharmaceutical markets: improving efficiency and controlling costs in the UK. International Journal of Health Planning and Management, 20: 375-398.
88. Wells, L. T. (1983) Third World Multinationals: The Rise of Foreign Investments from Developing Countries. Cambridge, MA: MIT Press.
89. Witt, M. A., Lewin, A. Y. (2007) Outward foreign direct investment as escape response to home country institutional constraints. Journal of International Business Studies, 38: 579-594.
90. Yiu, D. W., Lau, C., Bruton, G. (2007) International venturing by emerging economy firms: the effects of firm capabilities, home country networks, and corporate entrepreneurship. Journal of International Business Studies, 38: 519-540.
91. Zeller, C. (2004) North Atlantic innovation relations of Swiss pharmaceuticals and the proxies with regional biotech areas. Economic Geography, 80: 83-111.